I will post some of the answers from the AMA
Agent248 thanks for your questions. With respect to CC Pharma recording cannabis related revenue, I think I should clarify a couple of things. CC Pharma does not grow cannabis and technically wont ever record revenue from growing cannabis. CC Pharma is a distribution business. It will record revenue from distributing cannabis as soon as we are able to import cannabis into Germany under EU-GMP certification or as soon as Aphria Deutschland completes its first harvest of cannabis. In the interim period, CC Pharma is setting up its business for distributing cannabis. It also maintains a small distribution agreement with a company call EMMAC for distributing cannabis in Germany, once EMMAC secures all required permits, licenses and supply. Colcannas construction continues to advance. Irwin and I were in Colombia recently and came back very impressed with the opportunity in Colombia. What became clear during our trip is that the Colombian market has been slower to develop due determining the appropriate way to establish GMP standards in Colombia. What also became clear was just how big the opportunity in South America is (650M people, medical benefits, etc.). Taking advantage of Colombias equatorial position and using that as a growing hub to feed the continent presents a tremendous opportunity for Aphria. To do that, we will need to secure GMP certification for the grow and infrastructure, but the opportunity is just too large to not take that step. The first big step for us in Colombia was land levelling, which is complete. The next step is build-out of the greenhouses and infrastructure. Aphria has secured all required licenses for Colombia, except for GMP certification, which the government is still trying to establish. In the interim, while those steps are occurring, we are working on securing EU-GMP certification in Canada, to allow us to temporarily export product out of Canada and import it into LATAM to generate LATAM sales earlier. The government in Argentina recently passed new rules on their special access program and the advance work we did with Hospital Garrahan on the pediatric epilepsy trial has positioned us very well in LATAM to leverage the Aphria medical brand. Vic is no longer involved with Aphria, other than as a shareholder.